glp-1 agonists market Weight Loss Drugs Report, 2025-2030 GLP-1 Receptor Agonist Market Size

While GLP-1-based medications do not directly cause back pain through their primary mechanism of action, several indirect factors may contribute to musculoskeletal discomfort during treatment

Its growth was driven by expanded adoption across multiple myeloma treatment regimens, including frontline and relapsed/refractory settings, as well as the convenience of the subcutaneous formulation, which reduces administration time and improved patient experience

doi: 10.1007/s00125-022-05722-5 25 VerbeetenKCElksCEDanemanDOngKK

GLP-1 based therapies and disease course of inflammatory bowel disease

Most patients stay on GLP-1s for 15 months, depending on their weight loss goals, how their body responds, and how well they tolerate the medication

Gagnon J, Anini Y